Healthcare provider profile · identity verified

Marilyn S Kellam, MD

Internal Medicine · NORFOLK, VA · NPI 1497740641

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Sertraline Hcl	Sertraline Hcl	257	32
Gabapentin	Gabapentin	218	11
Eliquis	Apixaban	161	suppressed
Donepezil Hcl	Donepezil Hcl	112	11
Quetiapine Fumarate	Quetiapine Fumarate	102	15
Amlodipine Besylate	Amlodipine Besylate	101	16
Memantine Hcl	Memantine Hcl	101	16
Furosemide	Furosemide	99	15
Atorvastatin Calcium	Atorvastatin Calcium	90	17
Levothyroxine Sodium	Levothyroxine Sodium	83	suppressed
Carvedilol	Carvedilol	82	suppressed
Hydralazine Hcl	Hydralazine Hcl	78	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	77	12
Diclofenac Sodium	Diclofenac Sodium	74	11
Omeprazole	Omeprazole	73	12
Metoprolol Tartrate	Metoprolol Tartrate	72	suppressed
Loperamide	Loperamide Hcl	63	34
Divalproex Sodium	Divalproex Sodium	60	suppressed
Aripiprazole	Aripiprazole	57	17
Nifedipine Er	Nifedipine	53	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	53	suppressed
Levetiracetam	Levetiracetam	50	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	49	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	suppressed
Risperidone	Risperidone	47	11
Lorazepam	Lorazepam	43	suppressed
Tramadol Hcl	Tramadol Hcl	43	suppressed
Ipratropium Bromide	Ipratropium Bromide	42	suppressed
Clopidogrel	Clopidogrel Bisulfate	40	suppressed
Losartan Potassium	Losartan Potassium	40	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	36	suppressed
Trazodone Hcl	Trazodone Hcl	36	suppressed
Mirtazapine	Mirtazapine	35	suppressed
Duloxetine Hcl	Duloxetine Hcl	33	suppressed
Latanoprost	Latanoprost	32	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Alprazolam	Alprazolam	28	suppressed
Baclofen	Baclofen	28	suppressed
Xarelto	Rivaroxaban	27	suppressed
Potassium Chloride	Potassium Chloride	26	suppressed
Clonidine	Clonidine	25	suppressed
Folic Acid	Folic Acid	25	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	25	suppressed
Buspirone Hcl	Buspirone Hcl	22	suppressed
Lisinopril	Lisinopril	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	21	suppressed
Cephalexin	Cephalexin	21	14
Albuterol Sulfate Hfa	Albuterol Sulfate	20	suppressed
Lubiprostone	Lubiprostone	20	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	20	suppressed
Amiodarone Hcl	Amiodarone Hcl	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Metoprolol Succinate	Metoprolol Succinate	17	suppressed
Combigan	Brimonidine Tartrate/Timolol	16	suppressed
Glipizide	Glipizide	16	suppressed
Nuplazid	Pimavanserin Tartrate	15	suppressed
Nitroglycerin Patch	Nitroglycerin	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	13	13
Bumetanide	Bumetanide	13	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Nystatin	Nystatin	13	suppressed
Albuterol Sulfate	Albuterol Sulfate	12	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	12	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Prednisone	Prednisone	12	suppressed
Amantadine	Amantadine Hcl	11	suppressed
Lactulose	Lactulose	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error